周长林，男，1964年1月生，1986、1989和1997年于华东理工大学生物工程专业分别获学士、硕士和博士学位，1999.4-2000.3年日本近畿大学药学部访问学者，2004.12-2005.11年美国Providence College生物系博士后，教授、博士生导师。曾担任中国药科大学生命科学与技术学院副院长、微生物学教研室主任；现为国家药品评审专家、国家基金委评审专家、国家国际科技合作专项项目评审专家、中国博士后科学基金评审专家，担任中国微生物学会酶工程专业委员会委员、江苏省第十一届生物化学和分子生物学学会副理事长, 《中国药科大学学报》、《药物生物技术》等杂志编委。2008年被评为江苏省“青蓝工程”中青年学术带头人。长期从事微生物与生化药学教学和研究工作，主要研究方向为抗感染药物药效及分子机制研究、免疫抗肿瘤药物活性及机制研究。主持多项国家、省部级和横向科研课题。至今发表研究论文近100篇，其中SCI收录60余篇，申请多项发明专利，主编出版《微生物学》、《微生物学与免疫学》和《微生物学实验与指导》等教材（中国医药科技出版社）。
抗感染、抗肿瘤药物活性及分子机制。
（1）国家卫健委十三五“新药创制”科技重大专项，I类新药抗真菌多肽PL-18和抗耐药菌多肽Cbf-14临床前研究，2019ZX09721001-004-005，244万元，2019-2020。
（2）国自然面上项目，基于MCR-1修饰LPS介导的细菌免疫逃逸探讨新结构多肽MSI-1抗多黏菌素耐药感染的机制（82173863），55万元，2021-2024。
（3）国自然面上项目，基于多靶点的多肽抗耐药性细菌感染的机制研究（81673483），45万元，2017-2020。
（4）江苏省自然科学基金面上项目，基于LPS识别模式的多肽调节mcr-1抗多粘菌素耐药菌感染的宿主免疫防御机制, BK20201327,10万元，2020-2023。
(1) Wang L, Liu M, Qi Y, Wang J, Shi Q, Xie X, Zhou C*, Ma L*. hsdSA regulated extracellular vesicle-associated PLY to protect Streptococcus pneumoniae from macrophage killing via LAPosomes. Microbiol Spectr. 2024 Jan 11;12(1):e0099523. doi: 10.1128/spectrum.00995-23. Epub 2023 Nov 29.
(2) Xinyue Ye, Jian Wang, Pengfei Xu, Xiaoqian Yang, Qixue Shi, Genyan Liu, Zhaoshi Bai*, Changlin Zhou*, Lingman Ma*. Peptide MSI-1 inhibited MCR-1 and regulated outer membrane vesicles to combat immune evasion of Escherichia coli. Microbial biotechnology. 2023 Sep;16(9):1755-1773
(3) Chenyu Zhou, Meiling Jiang, Xinyue Ye, Xiaoyun Liu, Wenxuan Zhao, Lingman Ma, Changlin Zhou*. Antibacterial Activities of Peptide HF‑18 Against Helicobacter pylori and its Virulence Protein CagA. International Journal of Peptide Research and Therapeutics. 2022 Mar; 28(2)
(4) Lingman Ma1, XinyueYe1, Pengbo Sun, Pengfei Xu, Liping Wang, Zixiang Liu, Xiaowei Huang, Zhaoshi Bai, Changlin Zhou. Antimicrobial and antibiofilm activity of the EeCentrocin 1 derived peptide EC1-17KV via membrane disruption. Ebiomedicine. 2020 May; 55: 102775
(5) Lingman Ma1, Xin Xie1, Hanhan Liu, Ya Huang, Haomin Wu, Meiling Jiang, Pengfei Xu, Xinyue Ye, Changlin Zhou*. Potent antibacterial activity of MSI-1 derived from the magainin 2 peptide against drug-resistant bacteria. Theranostics. 2020 Jan 1;10(3):1373-1390
(6) Meiling Jiang, Xiaoqian Yang, Haomin Wu, Ya Huang, Jie Dou, Changlin Zhou*, Lingman Ma*. An active domain HF-18 derived from hagfish intestinal peptide effectively inhibited drug-resistant bacteria in vitro/vivo. Biochemical Pharmacology. 2020 Feb; 172:113746
(7) Xin Xie1, Lingman Ma1, Yiran Zhou 1, Wen Shen, Duiyue Xu, Jie Dou, Baiyong Shen*, Changlin Zhou*. Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. Carbohydrate Polymers. 2019 Dec 1; 225: 115223
(8) Wei Kang, Hanhan Liu, Lingman Ma, Mengxiao Wang, Shanshan Wei, Pengbo Sun, Meiling Jiang, Min Guo, Changlin Zhou*, Jou Dou*. Effective antimicrobial activity of a peptide mutant Cbf-14-2 against penicillin-resistant bacteria based on its unnatural amino acids. European Journal of Pharmaceutical Science. (2017), 105:169-177
(9) Xin Xie, Yiran Zhou, Xue Wang, Jian Guo, Jingwen Li, Hongye Fan, Jie Dou, Baiyong Shenb*, Changlin Zhou*. Enhanced antitumor activity of gemcitabine bypolysaccharide-induced NK cell activation and immune cytotoxicityreduction in vitro/vivo. Carbohydrate Polymers, 173 (2017) 360–371
(10) Lingman Ma, Yanrong Wang, Mengxiao Wang, Yuwei Tian, Wei Kang, Hanhan Liu, Hui Wang, Jie Dou*, Changlin Zhou*. Effective antimicrobial activity of Cbf-14, derived from a cathelin-like domain, against penicillin-resistant bacteria. Biomaterials (2016). 87: 32-45
(11) Mengyun Ke, Hui Wang, Min Zhang, Yuwei Tian, Yizhou Wang, Bing Li, Jie Yu, Jie Dou, Tao Xi, Changlin Zhou*. The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo. Biochemical Pharmacology, 2014, 89: 119-130
